Syntax Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Syntax Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$232K	Sell	282 -25	-8%	-$19.6K	0.2%	136
2023 Q2	$221K	Sell	307 -13	-4%	-$10K	0.18%	174
2023 Q1	$263K	Hold	320	–	–	0.2%	125
2022 Q4	$231K	Sell	320 -39	-11%	-$28.8K	0.19%	150
2022 Q3	$247K	Sell	359 -66	-16%	-$41.5K	0.21%	117
2022 Q2	$251K	Buy	425 +66	+18%	+$42.9K	0.21%	121
2022 Q1	$251K	Sell	359 -31	-8%	-$19.6K	0.21%	132
2021 Q4	$246K	Buy	+390	New	+$240K	0.18%	177

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Syntax Advisors's REGN Position: Q3 2023 in Review

Syntax Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 8.1% in Q3 2023, selling an estimated $19.6K and leaving 282 shares worth $232K. The position accounts for 0.2% of the portfolio, ranked #136.

Syntax Advisors first reported a position in REGN in Q4 2021 and has held it in 8 quarters since. The position peaked at $263K in Q1 2023. 1,177 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

Syntax Advisors held 282 shares of Regeneron Pharmaceuticals worth $232K as of Q3 2023.
Syntax Advisors sold 25 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $19.6K.
Regeneron Pharmaceuticals made up 0.2% of Syntax Advisors's portfolio in Q3 2023, its #136 holding.
Syntax Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
Syntax Advisors's Regeneron Pharmaceuticals position peaked at $263K in Q1 2023.
1,177 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Syntax Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.